Human epidermal receptor-2 expression in prostate cancer - PubMed (original) (raw)
Affiliations
- PMID: 12631612
Human epidermal receptor-2 expression in prostate cancer
Benjamin F Calvo et al. Clin Cancer Res. 2003 Mar.
Abstract
Purpose: Efforts to conclusively establish that human epidermal receptor (HER)-2 overexpression is important to androgen-dependent carcinoma of the prostate (AD-CaP) or to progression to androgen independence (AI-CaP) have failed because of variability in tissue procurement, antibodies, immunostaining procedures, and assessment methods. However, because some in vitro and animal model data correlate HER-2 overexpression with progression to androgen independence, trials of agents that target the HER-2 receptor are under way. To clarify human tumor findings, we studied HER-2 expression at the gene (DNA), mRNA, and protein levels in well-characterized CaP specimens.
Experimental design: Fifty AD-CaP and 25 AI-CaP specimens from similar numbers of Caucasian and African Americans were immunostained for HER-2 receptor. HER-2 mRNA levels were measured using real-time fluorescence quantitative PCR in patients for whom frozen specimens were available. HER-2 amplification was evaluated using fluorescent in situ hybridization.
Results: HER-2 receptor immunostained in 52% of androgen-dependent and one (4%) androgen-independent tumor. HER-2 immunostaining was not related to age, race, serum prostate-specific antigen levels, or pathologic stage and Gleason grade. HER-2 overexpression was not detected in AI-CaP at the mRNA or gene level. Mean HER-2 mRNA expression was higher (P < 0.05) in AD-CaP than AI-CaP (22,080 versus 15,496 HER-2 copies). HER-2 was not amplified in any of 20 AD-CaP or 19 AI-CaP specimens.
Conclusions: HER-2 protein and message overexpression and HER-2 amplification were not found in AI-CaP.
Similar articles
- HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT. Press MF, et al. Clin Cancer Res. 2008 Dec 1;14(23):7861-70. doi: 10.1158/1078-0432.CCR-08-1056. Clin Cancer Res. 2008. PMID: 19047115 - Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F. Di Lorenzo G, et al. Clin Cancer Res. 2002 Nov;8(11):3438-44. Clin Cancer Res. 2002. PMID: 12429632 - Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G. Rosner IL, et al. Urology. 2007 Dec;70(6):1225-9. doi: 10.1016/j.urology.2007.09.010. Urology. 2007. PMID: 18158066 - A potential role for activated HER-2 in prostate cancer.
Agus DB, Akita RW, Fox WD, Lofgren JA, Higgins B, Maiese K, Scher HI, Sliwkowski MX. Agus DB, et al. Semin Oncol. 2000 Dec;27(6 Suppl 11):76-83; discussion 92-100. Semin Oncol. 2000. PMID: 11236032 Review. - HER-2/neu receptor in prostate cancer development and progression to androgen independence.
Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR, De Placido S. Di Lorenzo G, et al. Tumori. 2004 Mar-Apr;90(2):163-70. doi: 10.1177/030089160409000201. Tumori. 2004. PMID: 15237576 Review.
Cited by
- To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy.
Zhang KX, Firus J, Prieur B, Jia W, Rennie PS. Zhang KX, et al. Cancers (Basel). 2011 Mar 24;3(2):1498-512. doi: 10.3390/cancers3021498. Cancers (Basel). 2011. PMID: 24212771 Free PMC article. - Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization.
Baek KH, Hong ME, Jung YY, Lee CH, Lee TJ, Park ES, Kim MK, Yoo JH, Lee SW. Baek KH, et al. Cancer Res Treat. 2012 Mar;44(1):50-6. doi: 10.4143/crt.2012.44.1.50. Epub 2012 Mar 31. Cancer Res Treat. 2012. PMID: 22500161 Free PMC article. - Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.
Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boyé K, de Cremoux P, Dutrillaux B, Poupon MF. Legrier ME, et al. Br J Cancer. 2007 Jan 29;96(2):269-76. doi: 10.1038/sj.bjc.6603553. Epub 2007 Jan 9. Br J Cancer. 2007. PMID: 17211467 Free PMC article. - Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth.
Chuang TD, Chen SJ, Lin FF, Veeramani S, Kumar S, Batra SK, Tu Y, Lin MF. Chuang TD, et al. J Biol Chem. 2010 Jul 30;285(31):23598-606. doi: 10.1074/jbc.M109.098301. Epub 2010 May 24. J Biol Chem. 2010. PMID: 20498373 Free PMC article. - Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.
Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW. Veltri RW, et al. Prostate. 2008 Dec 1;68(16):1806-15. doi: 10.1002/pros.20848. Prostate. 2008. PMID: 18767028 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous